生物标志物引导的围术期炎症调控与免疫代谢支持与超低位前切除术后恢复和生存改善相关
该前瞻性非随机对照队列纳入198例I-III期直肠腺癌患者,比较ERAS护理与生物标志物引导的多组分靶向干预(围术期炎症调控联合免疫代谢支持)。干预组在抑郁、睡眠、性功能及肛门直肠功能等多域恢复指标上均优于对照,2年无病生存率和总生存率更高。
要点
- 干预从术前14天持续至术后6个月,联合短链脂肪酸、益生菌和ω-3脂肪酸。
- 干预组复合应答率69.2%,对照组35.4%,多域功能评分均显著改善。
- 干预组2年DFS 91.0% vs 77.1%,OS 94.6% vs 82.3%。
核心结论
- 生物标志物引导的围术期炎症调控联合免疫代谢支持与超低位前切除术后多域恢复和生存改善相关。
- 结论需在随机多中心试验中进一步验证。
研究设计与样本
- 前瞻性非随机对照队列研究,纳入198例I-III期直肠腺癌患者,研究期为2021年4月至2023年4月。
- 患者接受ERAS护理或生物标志物引导的多组分靶向干预,干预自术前14天持续至术后6个月。
主要发现
- 干预组BDI-II降低4.5、PSQI降低3.3、IIEF-5升高4.9、FSFI升高5.4、LARS降低6.8,所有p<0.01。
- 干预组复合应答率69.2%,对照组35.4%。
- 第7天CRP、IL-6和TNF-α更低,T细胞恢复增强,SMI下降减轻(-1.2% vs -3.8%,p<0.001)。
- 恢复加速、住院时间缩短、并发症减少。
- 中位随访25.3个月时,2年DFS为91.0% vs 77.1%(HR 0.44,p=0.015),OS为94.6% vs 82.3%(HR 0.39,p=0.018)。
关键数值与推荐
- 干预组合:短链脂肪酸、益生菌和ω-3脂肪酸,以CRP、IL-6和TNF-α为指导。
- 个体化优化包括T细胞谱分析、骨骼肌保护和定制营养。
- 主要终点为24个月内BDI-II、PSQI、IIEF-5/FSFI和LARS评估的抑郁症状、睡眠质量、性功能和肛门直肠功能。
- 次要终点包括炎症标志物、骨骼肌指数(SMI)和生存。
临床怎么用
- 对超低位前切除术后患者,可考虑围术期炎症调控联合免疫代谢支持以改善多域功能恢复。
- 利用CRP、IL-6、TNF-α等生物标志物指导个体化营养与免疫代谢干预。
- 关注骨骼肌保护与T细胞免疫恢复作为围术期管理组成部分。
局限性
- 为非随机对照设计,存在选择偏倚可能。
- 结论需随机多中心试验确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ultra-low anterior resection (ULAR) preserves sphincter function for low rectal cancer but often causes bowel, sexual, sleep, and psychological dysfunction, impairing recovery and survival. Persistent inflammation and immunometabolic dysregulation contribute significantly. We evaluated whether perioperative inflammatory modulation plus biomarker-guided immunometabolic support improved recovery and outcomes after ULAR. METHODS: In this prospective nonrandomized cohort, 198 patients with stage I-III rectal adenocarcinoma (April 2021-April 2023) received ERAS care or a biomarker-guided multicomponent targeted intervention combining perioperative inflammatory modulation and immunometabolic support. The intervention began 14 days preoperatively and continued 6 months, combining short-chain fatty acids, probiotics, and ω-3 fatty acids guided by C-reactive protein, interleukin-6, and tumor necrosis factor-α with individualized optimization (T-cell profiling, skeletal muscle preservation, tailored nutrition). Primary endpoints were depressive symptoms (BDI-II), sleep quality (PSQI), sexual function (IIEF-5/FSFI), and anorectal function (LARS) over 24 months. Secondary endpoints included inflammatory markers, skeletal muscle index (SMI), and survival. RESULTS: The intervention improved BDI-II (- 4.5), PSQI (- 3.3), IIEF-5 (+ 4.9), FSFI (+ 5.4), and LARS (- 6.8; all p < 0.01), with 69.2% achieving composite response versus 35.4% of controls. Day-7 CRP, IL-6, and TNF-α were lower; T-cell recovery enhanced; and SMI decline attenuated (- 1.2% vs. - 3.8%; p < 0.001). Recovery accelerated, hospitalization shortened, and complications decreased. At 25.3 months, 2-year DFS (91.0% vs. 77.1%; HR 0.44; p = 0.015) and OS (94.6% vs. 82.3%; HR 0.39; p = 0.018) were higher. CONCLUSION: A biomarker-guided perioperative program integrating inflammatory modulation and immunometabolic support was associated with improved multidomain recovery and survival after ULAR. Confirmation in randomized multicenter trials is warranted.
引用
- Wang G, Pan S. Biomarker-guided perioperative inflammatory modulation and immunometabolic support are associated with improved recovery and survival after ultra-low anterior resection: a prospective nonrandomized controlled cohort study. Surg Endosc. 2025. PMID: 41162755. doi:10.1007/s00464-025-12344-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。